Transcript Richard Salives

Synchronised Calls
Concept and Funding
The Inserm’s position
Richard Salives
European Affairs Director, Inserm
Synchronised calls meeting / European Commission
Brussels - January 15, 2014
INSERM
• Created in 1963, related to both Ministry of Research and Ministry
of Health
• The only French public organisation entirely dedicated to
biological, medical and public health research
• The largest European RPO devoted to biomedical research
• Excellence and multidisciplinary research programmes on
most human diseases, even the rarest ones
• The link between the research laboratory and the hospital bed
Life and health sciences progress for better and affordable
health care for patients
INSERM IN FIGURES
(YEAR 2012)
 Budget: 953.6 M€ (incl. salaries)
 Human resources: 13,357 FTE
5,039 permanent staff (2 153 researchers)
2,689 contractual positions
4,030 university-hospital personnel
854 foreign researchers
 Research teams: 986
 Inserm publications: 9,727
47,4% international co-publications
 Patents: 1,083 families
57 licence contracts
289 R&D contracts
 FP7 (2007-2013):
36 coordinations
108 ERC laureates
INSERM IN EUROPE
Inserm in the FP7
 Participates mainly in Health priority,
ERC, IMI & BMS ESFRI

4.4% coordinated by Inserm
Joint Programming Initiative
(JPI)

Alzheimer’s disease

Antimicrobial resistance
 40% of FP7 Health research projects
coordinated by French teams

4.4% coordinated by Inserm (1st
position)
 Participation in 21,5% of the FP7
Health research projects (1st position)
 One of the first positions in ERC : 56 StG
(from 2007), 12 CoG (2013) and 40 AdG (from
2008)
 7 BMS ESFRI projects:
ECRIN, ERINHA (coordinator)
BBMRI, EUROBIOIMAGING,
INFRAFRONTIER, ELIXIR, INSTRUCT
Next FP : Horizon 2020
 Societal challenges, ERC,
Marie Curie Actions,
Infrastructures, Future and
emerging technologies, EIT
(KIC Healthy Ageing)
Science Europe (former representative of
RPOs)
The French National Alliance
for Life Sciences and Health
April 9, 2009
Aviesan’s members
Associate members
5
www.aviesan.fr/en
10 “WITHOUT WALLS” THEMATIC INSTITUTES
Molecular and
structural
bases of living
organisms
Cell biology,
development
and evolution
Cancer
Circulation,
metabolism,
and nutrition
Genetics,
genomics and
bioinformatics
INCa
Immunology,
hematology,
and
pneumology
Microbiology
and infectious
diseases
Neurosciences,
cognitive
sciences,
neurology and
psychiatry
ANRS
Alzheimer
Public Health
(and
environmental
medical
sciences)
IReSP
Health
Technologies
Aviesan objectives
http://www.aviesan.fr/en
Scientific
coordination
Operational
coordination
To coordinate strategic analysis,
scientific programming and the
operational implementation of research
in Life Sciences and Health
To define common positions at the
European and International levels
To give a boost to translational
research
To reinforce the partnerships between
research institutions and universities
To encourage trans-disciplinarity
To promote the dissemination of
Knowledge and the use of discoveries
To simplify the administrative
procedures for the daily-life of
laboratories and researchers
7
Decision-making institution?
INSERM’S
POSITION
FRANCE
MS
POSITION
ANR
POSITION
One French RPO
FRENCH
RPO’S
POSITION
SE MOs
POSITION
Synchronised Calls: benefits and obstacles
 Call published on Dec. 11, 2013 – Horizon 2020 / Challenge N°6
H2020-INSO-2014
 Deadline: April 29, 2014
 CSA 2 years / Up to 5 Synchronised call initiatives funded
(EC funding: evaluation process co-funding, implementation and
coordination costs…)
 At least 3 legal entities established in 3 different MS or AC
Synchronised Calls: benefits
 Improvement of the evaluation systems (joint peer review evaluation
/ transparency /similar treatment for proposals)
 Improvement of the effectiveness of the national research systems
 Improvement of the efficiency of research funding (no duplication)
Benefits for Inserm:
 Benchmarking for scientific strategies
 Participation to the construction of the ERA
Synchronised Calls: Obstacles
 Short-time limit: deadline April 29, 2014
 Necessary involvement of the National funding agencies of the
« countries of excellence » like Germany, UK, France, Italy, Spain…
 Would it be a successful initiative without the main European research
actors?
 Important to avoid national calls on the same topic
Synchronised Calls Initiative
 Inserm supportive of the initiative
 Inserm is a RPO  participation only if involvement
of the National funding agency
Thank you
for your attention